acc late breaking clinical trial session march 11, 2013, san francisco, ca
DESCRIPTION
Digoxin Reduces 30-Day All-Cause Hospital Admission in Ambulatory Older Patients with Chronic Heart Failure and Reduced Ejection Fraction. ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA . - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/1.jpg)
Digoxin Reduces 30-Day All-Cause Hospital Admission in Ambulatory Older Patients with Chronic Heart Failure and Reduced
Ejection Fraction
Ali Ahmed, Mihai Gheorghiade, Gregg Fonarow, Kanan Patel, Inmaculada Aban, Richard Allman, Jerome Fleg, Robert Bourge
University of Alabama at Birmingham Veterans Affairs Medical Center
Birmingham, AL
ACC Late Breaking Clinical Trial SessionMarch 11, 2013, San Francisco, CA
![Page 2: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/2.jpg)
Presenter Disclosure Information
DISCLOSURE INFORMATION:No relationships exist related to this presentation
Ali Ahmed, MD, MPH
Digoxin Reduces 30-Day All-Cause Hospital Admission in Ambulatory Older Patients with Chronic Heart Failure and
Reduced Ejection Fraction
Dr. Ahmed was supported in part by the National Institutes of Health through grants (R01-HL085561, R01-HL085561-S and R01-HL097047)
from the National Heart, Lung, and Blood Institute (NHLBI)
![Page 3: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/3.jpg)
The Digitalis Investigation Group (DIG) trial was supported by the NHLBI and the VA Cooperative Studies Program
This article was prepared using a limited access dataset obtained from the NHLBI
and does not necessarily reflect the opinions or views of the DIG Study or the
NHLBI.
Funding Disclosure Information
![Page 4: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/4.jpg)
New Perspective on an Old Drug
A Very Old Drug
![Page 5: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/5.jpg)
Discovered Over 2 Centuries AgoAn Account of the Foxglove and Some of its Medical Uses
William Withering1785
![Page 6: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/6.jpg)
N Engl J Med 1993; 329:1-7
Patients whose digoxin was discontinued (in the placebo group) had a higher risk of worsening heart failure (HR, 5.9; 95% CI = 2.1 to 17.2; P<0.001)
N=23
N=4
Improves Heart Failure Symptoms(The RADIANCE Trial)
![Page 7: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/7.jpg)
N Engl J Med. 1997; 336: 525-33
Digoxin significantly reduced the risk of hospitalization due to heart failure by 28% during 37 months of average
follow-up, but its effect on hospitalization due to all causes was more modest (a 8% reduction)
Placebo(n=3403)
Digoxin(n=3397)
Absolute RiskDifference
Hazard ratio (95% CI) P value
Heart Failure 35% 27% –8% 0.72 (0.66–0.79) <0.001
All-Cause 67% 64% –3% 0.92 (0.87–0.98) 0.006
Reduces Risk of Hospital Admission (The DIG Trial)
![Page 8: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/8.jpg)
N Engl J Med. 1997; 336: 525-33
HR = 0.99;95% CI = 0.91–1.07;P = 0.80
Does Not Increase Mortality(The DIG Trial)
![Page 9: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/9.jpg)
In 1997, FDA approved digoxin for use in heart failure
Approved by the FDA
![Page 10: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/10.jpg)
Recommended by Guidelines
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
JACC. 2009 doi:10.1016/j.jacc.2008.11.013
Digitalis can be beneficial in patients with current or prior symptoms of HF and reduced
LVEF to decrease hospitalizations for HF
Recommendation Class: IIa Level of Evidence: B
![Page 11: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/11.jpg)
• SOLVD (1991): 66%• US Carvedilol (1996): 90%• RALES (1999): 73%
• CHARM-Alternative (2003): 45%• RAFT (2010): 35%• EMPHASIS (2011): 27%
over the subsequent decades…in part due to lack of effect on death and downgrade in guideline recommendations
However, Use Declined
![Page 12: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/12.jpg)
N Engl J Med 2009;360:1418-28
Yet, Heart Failure Remains the Leading Reason for Hospital Admission and Readmission
Condition at Index Discharge
30-Day All-Cause Readmission
Most Frequent Reason for Readmission
All Medical 21.0% Heart Failure (8.6%)
Heart Failure 26.9% Heart Failure (37.0%)
All Surgical 15.6% Heart Failure (6.0%)
![Page 13: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/13.jpg)
March 2010
The New Health Care Reform Act Signed into Law
Requires CMS to reduce payments to hospitals with excess readmissions,
effective October 1, 2012…
![Page 14: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/14.jpg)
October 2012
Medicare imposed about $300 million financial penalties against
over 2,000 hospitals that had excessive readmission
![Page 15: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/15.jpg)
Objective
• To examine the effect of digoxin on 30-day all-cause hospital admission in older, potentially Medicare-eligible, adults with heart failure and reduced ejection fraction in the main DIG trial
![Page 16: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/16.jpg)
Digitalis Investigation Group (DIG)• Ambulatory chronic heart failure (N=6800) – Ejection fraction ≤45%– Normal sinus rhythm – From United States and Canada – Randomized to receive either digoxin or placebo– During 1991-1993 – Followed for an average of 3 years– >90% on ACE inhibitors and >80% on diuretics
• 3405 (50% of 6800) were ≥65 years of age
![Page 17: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/17.jpg)
Baseline Characteristics (1) Variables n (%) or mean (±SD)
Placebo(n=1712)
Digoxin(n=1693) P value
Age (years) 72 (5) 72 (5) 0.974Female 426 (25%) 415 (25%) 0.802Non-whites 194 (11%) 180 (11%) 0.514Body mass index (kg/m2) 26.2 (4.7) 25.9 (4.5) 0.040Heart rate (per minute) 78 (12) 78 (12) 0.445Systolic BP (mm Hg) 128 (20) 128 (20) 0.643Serum creatinine (mg/dL) 1.4 (0.4) 1.4 (0.4) 0.938LVEF (%) 29 (9) 29 (9) 0.855Cardiothoracic ratio 0.54 (0.08) 0.54 (0.07) 0.855NYHA Class III-IV 602 (35%) 603 (36%) 0.599
![Page 18: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/18.jpg)
Baseline Characteristics (2) Variables n (%) or mean (±SD)
Placebo(n=1712)
Digoxin(n=1693) P value
Heart failure duration (mos) 30 (37) 30 (38) 0.625Prior myocardial infarction 1168 (68%) 1154 (68%) 0.969Current angina pectoris 489 (29%) 465 (28%) 0.476Hypertension 815 (48%) 784 (46%) 0.448Diabetes mellitus 517 (30%) 488 (29%) 0.379Chronic kidney disease 1038 (61%) 1045 (62%) 0.513Dyspnea on exertion 1323 (77%) 1306 (77%) 0.924Dyspnea at rest 386 (23%) 358 (21%) 0.3234 or more symptoms/signs 1411 (82%) 1384 (82%) 0.525Pulmonary edema by x-ray 266 (16%) 286 (17%) 0.283
![Page 19: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/19.jpg)
Baseline Characteristics (3) Variables n (%) or mean (±SD)
Placebo(n=1712)
Digoxin(n=1693) P value
Dose of study medication 0.125 mg/day 433 (25%) 426 (25%) 0.25 mg/day 1197 (70%) 1209 (72%) 0.430 0.375 mg/day or higher 71 (5%) 48 (3%)Pre-trial digoxin use 739 (43%) 744 (44%) 0.646ACE inhibitors 1605 (94%) 1591 (94%) 0.784Diuretics 1405 (82%) 1374 (81%) 0.493Nitroglycerines 788 (46%) 768 (45%) 0.697
Overall, ALL baseline characteristics of patients assigned to digoxin and placebo were balanced except for a slightly lower
BMI among those assigned to digoxin
![Page 20: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/20.jpg)
Kaplan-Meier Plot
30-D
ay A
ll-Ca
use
Hosp
ital A
dmis
sion
Follow-up in Days
![Page 21: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/21.jpg)
30-Day Hospital Admission Due to All Causes
Placebo(n=1712)
Digoxin(n=1693)
Absolute RiskDifference
Hazard ratio (95% CI)
P value
8.1% 5.4% –2.7% 0.66 (0.51–0.86) 0.002
In the 30 days after randomization, in patients assigned to digoxin, the absolute risk and relative risk for all-cause hospital
admission was reduced by an 2.7% and 34%, respectively
![Page 22: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/22.jpg)
60-Day and 90-Day All-Cause Hospital Admission
Hazard ratio (95% CI) P value
At 60 days 0.76 (0.63–0.91) 0.003
At 90 days 0.75 (0.63–0.88) <0.001
The effect of digoxin on 30-day all-cause hospital admission persisted during 60 and 90 days after randomization, suggesting the early benefit of digoxin was not at the cost of later harm
![Page 23: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/23.jpg)
Placebo(n=1712)
Digoxin(n=1693)
Absolute RiskDifference
Hazard ratio (95% CI)
P value
6.5% 3.5% –3.0% 0.53 (0.38–0.72) <0.001
In the 30 days after randomization, digoxin reduced the risk of hospital admission due to cardiovascular causes by 47%
30-Day Hospital Admission Due to Cardiovascular Causes
![Page 24: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/24.jpg)
Placebo(n=1712)
Digoxin(n=1693)
Absolute RiskDifference
Hazard ratio (95% CI)
P value
4.2% 1.7% –2.5% 0.40 (0.26–0.62) <0.001
In the 30 days after randomization, digoxin reduced the risk of hospital admission due worsening heart failure by 60%
30-Day Hospital Admission Due to Worsening Heart Failure
![Page 25: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/25.jpg)
30-Day Mortality
Hazard ratio (95% CI) P value
All-cause 0.55 (0.27-1.11) 0.096
Cardiovascular 0.64 (0.31-1.31) 0.222
Progressiveheart failure 0.22 (0.05-1.04) 0.056
Although few deaths (n=34) occurred, they were numerically fewer in the digoxin group (0.7% vs. 1.3% for placebo)…
![Page 26: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/26.jpg)
30-Day Combined Outcomes
Placebo(n=1712)
Digoxin(n=1693)
Absolute RiskDifference
Hazard ratio (95% CI)
P value
8.7% 6.0% –2.7% 0.69 (0.53–0.88) 0.003
…consequently, the composite outcome of all-cause hospitalization or all-cause death at 30 days also was reduced
substantially (by 31%)
Only 4 patients were hospitalized because of suspected digoxin toxicity within 30 days of randomization, of whom 3 were from the digoxin group
![Page 27: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/27.jpg)
Subgroup Analyses
![Page 28: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/28.jpg)
• Post hoc analysis of RCT• Generalizability concerns– Ambulatory vs. post-discharge– Admission vs. re-admission – HFrEF vs. HFpEF– Not receiving beta-blockers – Not receiving aldosterone antagonists
Study Limitations
![Page 29: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/29.jpg)
• Digoxin reduced the risk of 30-day all-cause hospital admission in ambulatory older adults with chronic systolic heart failure receiving ACE inhibitors and diuretics
• If these findings can be replicated in contemporary older heart failure patients discharged from hospital after acute decompensation, digoxin may provide an inexpensive tool to reduce 30-day all-cause hospital readmission
Conclusions
![Page 30: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/30.jpg)
“After all, in spite of opinion, prejudice or error, Time will fix the real value upon this discovery, and determine whether I have imposed upon myself and others, or contributed to the benefit of science and mankind.”
As Sir Withering Predicted in 1785
Dr. William Withering (1741-1799)
![Page 31: ACC Late Breaking Clinical Trial Session March 11, 2013, San Francisco, CA](https://reader036.vdocuments.us/reader036/viewer/2022062521/5681666d550346895dda0706/html5/thumbnails/31.jpg)
Advance Access Online Publication March 11, 2013